Beihai Biotech has developed a Proprietary Precision Delivery Technology Platform, which focuses on enhancing the delivery of therapeutic agents to improve patient outcomes. This platform is complemented by their Peptide-Drug Conjugate (PDC) technology, which aims to create more effective and targeted cancer treatments. The company is committed to innovation in drug development, with a robust pipeline that includes eight promising drug candidates targeting various types of cancer, such as breast cancer, non-small cell lung cancer, prostate cancer, and gastric adenocarcinoma.

One of the standout products from Beihai Biotech is BEIZRAY (BH009), an innovative formulation of docetaxel that has received FDA approval. This new formulation eliminates polysorbate 80, an emulsifying agent associated with severe allergic reactions, thereby enhancing clinical safety and reducing hematologic toxicity. BEIZRAY represents a significant advancement in cancer treatment, offering improved efficacy and a better risk-benefit profile for patients. The company is actively working to expand the availability of BEIZRAY in various global markets, which is expected to drive revenue growth and support further research and development initiatives.

China

Beihai Biotech is a clinical-stage biopharmaceutical company based in Zhuhai, China, that researches, develops, and produces safe anti-cancer drugs. The company is focused on developing innovative anti-tumor drugs to improve tumor treatments and provide a better life for patients.

Cancer

Chronic pain

Pathological Conditions

Building 2, No. 6366, Zhuhai Avenue, Jinwan District, Zhuhai, Guangdong 519090, China

Beihai Biotech

Company Details